ENZON PHARMACEUTICALS, INC. 8-K

What Happened

• Enzon Pharmaceuticals, Inc. (ENZN) announced on January 30, 2026 that it entered into a Seventh Amendment to its Section 382 Rights Agreement with Continental Stock Transfer & Trust Company (rights agent). The Seventh Amendment moves the Final Expiration Date of the rights to noon New York City time on March 2, 2026. The Rights Agreement was originally dated August 14, 2020.

Key Details

• Seventh Amendment executed: January 30, 2026; new Final Expiration Date: noon (NYC) on March 2, 2026.
• Rights agent: Continental Stock Transfer & Trust Company.
• The Rights Agreement has been previously amended multiple times (first amendment June 2, 2021; subsequent amendments through January 31, 2026) to extend Final Expiration Dates.
• Except for the change to the Final Expiration Date, the Rights Agreement remains unmodified; management states the extension is in the best interests of the company and its stockholders.

Why It Matters

• The amendment preserves the existing Section 382 rights framework for a limited additional period (until March 2, 2026). For investors, this means the protections or mechanisms established by the Rights Agreement remain in place through that date. Management’s stated rationale is that the extension is in the best interests of the company and its stockholders.